<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20130813014350N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-16</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Investigating growth factors and complications after implant treatment</public_title>
      <acronym></acronym>
      <scientific_title>A comparative study of the effect of leukocyte and fibrin-rich plasma (L-PRFin soft tissue thickness, tissue healing rate, pain and discomfort after peri-implant treatment in people needing dental implants (split- mouth randomized controlled trial)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>10</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65504</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to randomize the type of treatment on the left and right sides of the permuted block randomization method.
  randomization) with a block size of 4 will be used. Considering that A represents the right side and B represents the left side, the randomization process will be as follows (randomization was done with SAS version 9 software):


Seed: 51660630849336
Block sizes: 4
Actual list length: 8
block identifier, block size, sequence within block, treatment
•	1, 4, 1, Group B
•	1, 4, 2, Group B
•	1, 4, 3, Group A
•	1, 4, 4, Group A
•	2, 4, 1, Group B
•	2, 4, 2, Group B
•	2, 4, 3, Group A
•	2, 4, 4, Group A, Blinding description: This trial will be conducted in a double-blind manner. In this category of studies, there is no possibility of blinding the patient due to blood sampling when he is subjected to surgery for the purpose of the experimental group. Therefore, in the present study, the outcome evaluator will not know the type of sample to be evaluated, and also The analyst of the study results will not know about the studied groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Soft tissue thickness, tissue healing rate, pain and discomfort after treatment around dental implants.</hc_freetext>
      <i_freetext>This study will be an interventional split-moth study that examines the effect of using L-PRF on the success of dental implants in 1 target group and 1 control group. At the beginning of the plan, the consent form will be completed by the patient. Then, the patient's personal characteristics such as age, gender, medical history and drug use are recorded.(Checklist No. 1) In this study, 10 patients referring to the periodontal surgery department of Gilan Faculty of Dentistry who need to place implants in the mandibular premolars will be selected based on the inclusion criteria.After the external and intraoral examinations, each patient is given full training regarding the control of oral plaque, and if dental plaque is observed, they receive scaling and root planing. Measuring the thickness of the buccal soft tissue by periodontal probe in millimeters. It will be done. On the day of the surgery, the patient will first rinse his mouth with 0.12% chlorhexidine and we will use iodine as an extraoral antiseptic.Local anesthesia (lidocaine HCl 2% with epinephrine 1:100,000) will be injected. Preparation of L-PRF: 9 ml of whole blood is collected from each patient in a plastic tube and immediately centrifuged for 12 minutes at 2700 rpm (or power 400 g at room temperature in a DUO Quattro centrifuge (49 Rue Gioffredo, 06000 Nice, France) will be centrifuged by the relevant technician who is a research associate (resident), and because it takes less time, it is easier to prepare. Then the fibrin clot which is formed in the middle of the tube (exactly between the red blood cells below and the cell-free plasma in the upper part), after the upper plasma is removed, it is separated from the lower blood cells using sterile forceps and scissors and transferred to a sterile compress.After preparing the osteotomy cavity for implant placement, the samples are randomly placed in 2 groups: control group 1, where no material is placed around the implant, group 2, where L-PRF is placed around the implant on the buccal side under the flap. For all samples, the DENTIS implant is placed in two stages. In both groups, full coverage will be done using 0-4 Silk suture thread and in a simple loop. Gelofen was prescribed for patients before surgery and 6 hours after surgery to continue using it if there is pain. The patient is advised to avoid eating hard and sticky foods or using a toothbrush in the surgical area and not to use the removable prosthesis for a week. After a week, the suture is removed. The final restoration will be placed after 3 months. The surgery is performed by a periodontist and the evaluation of the samples is performed by a periodontist who is unaware of the type of samples. Patient follow-up by a research associate (resident) to evaluate clinical parameters at baseline and 6 weeks later to check the thickness of soft tissue around the implant as a primary outcome and to evaluate pain during 7 days after surgery (days 7, 3, 2, 1 ) and the amount of soft tissue improvement on day 7 and day 14 after surgery will be performed as a secondary outcome. Clinical parameters include soft tissue thickness (measured by periodontal probe in millimeters), patient pain (VAS index), soft tissue improvement (Landry Index) , which includes tissue color, BOP, epithelialization of wound margin, presence of tissue granulation And the presence of pus..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Comparison of the effect of leukocyte and fibrin-rich plasma on the change of soft tissue thickness, tissue healing rate, pain and discomfort after peri-implant treatment in people who need dental implants, a split mouth randomized controlled clinical trial.
All data can be shared after de-identifying individuals.

When:
6-12 months after result publication

To whom:
Researchers working in academic institutions

Conditions:
Use in higher level studies such as systematic review studies

Where to obtain:
Bardia@gums.ac.ir

How to obtain:
Documents for writing a review article (for example, an invitation letter from the desired journal) should be provided

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bardia Vadiati Saberi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Dentistry, Guilan University of Medical Sciences, Ring Fooman, Lacan Road, Rasht, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4194173774</zip>
        <telephone>+98 13 1326 3622</telephone>
        <email>bardia@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bardia Vadiati Saberi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Dentistry, Guilan University of Medical Sciences, Ring Fooman, Lacan Road, Rasht, Iran</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4188794755</zip>
        <telephone>+98 13 1326 3622</telephone>
        <email>bardia@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 20-60
Partial edentulous patient
The plaque index before surgery is less than 25%</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>smokers
Pregnant and lactating women
History of radiation therapy and chemotherapy
Patients with active symptoms of infection such as pain, swelling, pus and abscess
Untreated advanced periodontitis
Blood disease and diabetes
Hyperthyroidism
High blood pressure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>This study will be an interventional split-moth study that examines the effect of using L-PRF on the success of dental implants in 1 target group and 1 control group. At the beginning of the plan, the consent form will be completed by the patient. Then, the patient's personal characteristics such as age, gender, medical history and drug use are recorded.(Checklist No. 1) In this study, 10 patients referring to the periodontal surgery department of Gilan Faculty of Dentistry who need to place implants in the mandibular premolars will be selected based on the inclusion criteria.After the external and intraoral examinations, each patient is given full training regarding the control of oral plaque, and if dental plaque is observed, they receive scaling and root planing. Measuring the thickness of the buccal soft tissue by periodontal probe in millimeters. It will be done. On the day of the surgery, the patient will first rinse his mouth with 0.12% chlorhexidine and we will use iodine as an extraoral antiseptic.Local anesthesia (lidocaine HCl 2% with epinephrine 1:100,000) will be injected. Preparation of L-PRF: 9 ml of whole blood is collected from each patient in a plastic tube and immediately centrifuged for 12 minutes at 2700 rpm (or power 400 g at room temperature in a DUO Quattro centrifuge (49 Rue Gioffredo, 06000 Nice, France) will be centrifuged by the relevant technician who is a research associate (resident), and because it takes less time, it is easier to prepare. Then the fibrin clot which is formed in the middle of the tube (exactly between the red blood cells below and the cell-free plasma in the upper part), after the upper plasma is removed, it is separated from the lower blood cells using sterile forceps and scissors and transferred to a sterile compress.After preparing the osteotomy cavity for implant placement, the samples are randomly placed in 2 groups: control group 1, where no material is placed around the implant, group 2, where L-PRF is placed around the implant on the buccal side under the flap. For all samples, the DENTIS implant is placed in two stages. In both groups, full coverage will be done using 0-4 Silk suture thread and in a simple loop. Gelofen was prescribed for patients before surgery and 6 hours after surgery to continue using it if there is pain. The patient is advised to avoid eating hard and sticky foods or using a toothbrush in the surgical area and not to use the removable prosthesis for a week. After a week, the suture is removed. The final restoration will be placed after 3 months. The surgery is performed by a periodontist and the evaluation of the samples is performed by a periodontist who is unaware of the type of samples. Patient follow-up by a research associate (resident) to evaluate clinical parameters at baseline and 6 weeks later to check the thickness of soft tissue around the implant as a primary outcome and to evaluate pain during 7 days after surgery (days 7, 3, 2, 1 ) and the amount of soft tissue improvement on day 7 and day 14 after surgery will be performed as a secondary outcome. Clinical parameters include soft tissue thickness (measured by periodontal probe in millimeters), patient pain (VAS index), soft tissue improvement (Landry Index) , which includes tissue color, BOP, epithelialization of wound margin, presence of tissue granulation And the presence of pus.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The thickness of the soft tissue around the implant. Timepoint: Baseline and 6 weeks later. Method of measurement: Measurement by periodontal probe in mm.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Postoperative pain assessment. Timepoint: during 7 days after surgery (days1,2,3,7). Method of measurement: Visual analog scale(VAS) index.</sec_outcome>
      <sec_outcome>Soft tissue healing rate. Timepoint: Day 7 and day 14 after surgery. Method of measurement: (Landry Index) which includes tissue color, BOP, epithelialization of wound margin, presence of tissue granulation and presence of pus.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Dental Research Center, Guilan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-21</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>No. 103, Rose Building, Parvaneh Dead End, Koi Shahid Amini, Ahmadzadeh Blvd., Bostan Mellat Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
